Good news for chronic nerve pain sufferers…but it could have been better

The announcement on Friday last week that pregabalin (Lyrica) made it onto the Pharmacutical Benefits Scheme (PBS) is a huge relief for sufferers of chronic nerve pain.

It also means that the true cost of providing appropriate care to chronic pain sufferers can be better measured. Too many GPs and other doctors are forced to prescribe opioids for nerve pain when the evidence for their usefulness is known to be unconvincing. As previously mentioned in this column, long-term opioid therapy for non-cancer pain has limited benefits compared to the potential for reduced quality of life, even if the generally overstated risk of abuse and addiction is discounted. This is especially true for nerve pain, also known as neuropathic pain. The pain is simply generated in a way that opioid drugs don’t really influence.

In choosing to accept the PBAC recommendation to list pregabalin, we are finally seeing some movement on the issue of the scandalous undertreatment of chronic pain in Australia.

But Minister Plibersek and her bureaucrats have missed a big trick.

Gabapentin is an older drug with the same basic mechanism of action as pregabalin. It is out of patent and is manufactured by a number of generic manufacturers, including some Australian ones. Gabapentin will never be listed on the PBS despite its proven effectiveness because the company which originally held the patent is Pfizer. Pfizer also developed pregabalin, and will be the beneficiary of essentially all of the half a billion dollars that this listing will generate for it. There is no commercial imperative for them to reapply for gabapentin, which is what the current listing process demands.

However, if the Minister had insisted that gabapentin be listed alongside pregabalin, there would have been a cheaper alternative drug with the same mechanism of action, and which most experts agree is equally effective. Moreover, the financial rewards for treating neuropathic pain would not then all go to Pfizer, but would be split to include some home-grown generics.

It would have been a win all round. Doctors would have access to two first-line drugs instead of one to treat neuropathic pain. The PBAC could specify that gabapentin must be tried prior to pregabalin via the Authority system. Patients would have had the option of trying a different agent if they can’t tolerate the side effects of pregabalin (in our experience over the last four years of prescribing both drugs this happens a lot.) And finally the local generic drug manufacturers would get a share of the profit from treating locals more effectively.
The total cost of treating neuropathic pain more effectively would arguably also be less, as for lower doses gabapentin is more cost-effective and better tolerated than pregabalin.

The only losers from all this would be the Pfizer executives and shareholders.

So while I welcome with relief the news that pregablin will be available on the PBS, I can’t help thinking that we could have done better all around. We need both drugs to be available.

Michael Vagg does not work for, consult to, own shares in or receive funding from any company or organisation that would benefit from this article, and has no relevant affiliations.

Share the love

DO YOU HAVE BACK PAIN and live in Sydney?

or you do not currently have any pain conditions?
We are looking for people to take part in a study to help us understand more about the process of recovery from back pain.
We need to recruit two groups:
(1) People with recent onset of back pain lasting less than 3 weeks
(2) People who do not currently have back pain
You will be asked to undertake three assessments (approximately 2 hours each) over 4 months at the Physiotherapy Research Lab in the Centre for Physical Health at Macquarie University in Sydney.
You will receive $30 for each assessment to compensate you for your travel and your time involved in participating.
If you are interested and to register please visit our website or contact Dr Julia Hush.

Lorimer is coming to York!

In this first course in the UK for several years, Lorimer will lead you through his 'highlights of pain' tour, visiting the conceptual underpinnings of modern pain rehabilitation, cutting edge pain-related cognitive and clinical neuroscience, critical pain-related thinking, clinical reasoning and treatment principles.

From Painful Yarns, to Explaining Pain Better, to Biologically Based Graded Exposure, the Cortical Body Matrix and the Imprecision Hypothesis, it will be intense, but it will also be scientifically sound, evidence based, clinically applicable and fun!
WHEN: 20 – 21 May 2015
WHERE: National Science Learning Centre, University of York
Reserve your place: joanna@noigroup.com, phone +44(0) 1904737919

As a graduate student, I volunteered at my local community centre and the manager assigned me to run one of the weekly exercise classes offered to older people in the community. I found this experience highly rewarding and I was impressed by the enthusiasm of participants. The highlight of each class was teaching a series […]

Immediately following a spinal cord injury (SCI) patients enter a state of areflexia and muscle weakness that is gradually replaced by the recovery of neuronal and network excitability leading to improvements in residual motor function over time as well as to the development of spasticity (i.e. involuntary muscle spasms). Spasticity can lead to impairments in […]

We aim to…

facilitate and disseminate good clinical science research. We love comments that engage with the research and are constructive and respectful. No self-promotion of your particular therapy please (these comments get filed in the recycling bin).
We do not prescribe treatments.

All blog posts should be attributed to their author, not to BodyInMind. That is, BodyInMind wants authors to say what they really think, not what they think BodyInMind thinks they should think. Think about that!

BiM Section Editors

Chief Editor Lorimer Moseley PhD
University of South Australia & Neuroscience Research Australia

Archives

All blog posts should be attributed to their author, not to BodyInMind. That is, BodyInMind wants authors to say what they really think, not what they think BodyInMind thinks they should think. Think about that!

We aim to facilitate and disseminate good clinical science research. We love comments that engage with the research and are constructive and respectful. No self-promotion of your particular therapy please (these comments get filed in the recycling bin).
We do not prescribe treatments.